Case Studies

Case Studies

In May 2015, Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, completed a $27,600,000 IPO. Laidlaw & Co. was the first to initiate research coverage shortly after the IPO in June 2015. In June 2018, Laidlaw Capital Markets acted as financial advisor for a follow-on offering of $78,000,000 and again in September 2018 for $175,800,000. In April 2023, following positive results from their Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735, Laidlaw Capital Markets acted as Co-Manager for a follow-on offering of $250,000,000. Following the transaction, the Laidlaw Capital Markets team has continued to add value by making additional introductions to more than 50 companies and continuing to promote VKTX to investors. Viking’s market capitalization has risen from $90 Million at the time of the IPO to a current $1 Billion.

Go to MTEM.com

In May 2015, Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, completed a $27,600,000 IPO. Laidlaw & Co. was the first to initiate research coverage shortly after the IPO in June 2015. In June 2018, Laidlaw Capital Markets acted as financial advisor for a follow-on offering of $78,000,000 and again in September 2018 for $175,800,0003. In April 2023, following positive results from their Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735, Laidlaw Capital Markets acted as Co-Manager for a follow-on offering of $250,000,0004. Following the transaction, the Laidlaw Capital Markets team has continued to add value by making additional introductions to more than 50 companies and continuing to promote VKTX to investors. Viking’s market capitalization has risen from $90 Million at the time of the IPO to a current $1 Billion.

NLS Pharmaceutics, Inc. (NASDAQ: NLSP) a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders was formed in June 2015. In June 2022, Laidlaw Capital Markets began working with the NLSP team on a non-deal roadshow and scheduling over 100 meetings with healthcare investors over the following year. In September 2022, Dr. Yale Jen initiated research coverage. In October 2022, Laidlaw Capital Markets acted as sole placement agents on a $4,000,000 private placement. In December 2022, following positive Phase 2 data and positive interim open-label extension study data for their lead asset, Mazindol ER, for the treatment of narcolepsy, Laidlaw Capital Markets acted as Exclusive Introducing Broker for a Private Placement of $10,000,000 of up to $30,000,000.

Go to MTEM.com

NLS Pharmaceutics, Inc. (NASDAQ: NLSP) a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders was formed in June 2015. In June 2022, Laidlaw Capital Markets began working with the NLSP team on a non-deal roadshow and scheduling over 100 meetings with healthcare investors over the following year. In September 2022, Dr. Yale Jen initiated research coverage. In October 2022, Laidlaw Capital Markets acted as sole placement agents on a $4,000,000 private placement. In December 2022, following positive Phase 2 data and positive interim open-label extension study data for their lead asset, Mazindol ER, for the treatment of narcolepsy, Laidlaw Capital Markets acted as Exclusive Introducing Broker for a Private Placement of $10,000,000 of up to $30,000,0003.

Founded in 1999 as Capnia, Inc., Soleno Therapeutics (NASDAQ:SLNO) is a Redwood City, Calif.-based clinical-stage, biopharmaceutical company focused on treating rare diseases. Laidlaw & Co. initiated research coverage in July 2019. In October 2019, Laidlaw Capital Markets acted as Co-Manager for a follow-on offering of $15,400,000. Laidlaw Capital Markets again acted as Co-Manager for a follow-on offering of $50,000,000 in June 20203, and an additional $15,000,000 in March 2022. Following positive positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS), Laidlaw Capital Markets acted as Lead Manager for a $120,000,000 follow-on offering. Laidlaw’s Capital Markets team continues to work with the SLNO team to increase awareness with investors and remain a long-term partner to the company.

Go to MTEM.com

Founded in 1999 as Capnia, Inc., Soleno Therapeutics (NASDAQ:SLNO) is a Redwood City, Calif.-based clinical-stage, biopharmaceutical company focused on treating rare diseases. Laidlaw & Co. initiated research coverage in July 2019. In October 2019, Laidlaw Capital Markets acted as Co-Manager for a follow-on offering of $15,400,0002. Laidlaw Capital Markets again acted as Co-Manager for a follow-on offering of $50,000,000 in June 20203, and an additional $15,000,000 in March 2022. Following positive positive top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS), Laidlaw Capital Markets acted as Lead Manager for a $120,000,000 follow-on offering. Laidlaw’s Capital Markets team continues to work with the SLNO team to increase awareness with investors and remain a long-term partner to the company.

In May of 2014, Aldeyra Therapeutics (ALDX), a late-stage clinical development biotechnology company developing and commercializing next generation medicines for patients with immune mediated, ocular and systemic diseases completed a $12,000,000, retail centric IPO. Since then, the company has raised over $320,000,000. Laidlaw & Co. initiated research coverage shortly after the IPO in January 2015. Following the company’s IPO, Laidlaw’s Capital Markets team was introduced to (ALDX) and consummated a robust healthcare centric institutional roadshow effort. After 50+ introductions to potential investors, in January 2015 Laidlaw was the exclusive placement agent on their first financing since their IPO, an $8mm PIPE transaction, where we successfully helped institutionalize the company with some marquee shareholders, many of which are still partners to the company today. In September 2018, Laidlaw acted as Co-Manager in a follow-on offering for $72,187,500 and again in April 2021 for $125,000.000. Laidlaw’s Capital Markets team has stayed committed to continuing to working with the team at ALDX to make relevant introductions, build awareness in the name, and be a supportive long-term partner to the company.

Go to MTEM.com

In May of 2014, Aldeyra Therapeutics (ALDX), a late-stage clinical development biotechnology company developing and commercializing next generation medicines for patients with immune mediated, ocular and systemic diseases completed a $12,000,000, retail centric IPO. Since then, the company has raised over $320,000,000. Laidlaw & Co. initiated research coverage shortly after the IPO in January 2015. Following the company’s IPO, Laidlaw’s Capital Markets team was introduced to (ALDX) and consummated a robust healthcare centric institutional roadshow effort. After 50+ introductions to potential investors, in January 2015 Laidlaw was the exclusive placement agent on their first financing since their IPO, an $8mm PIPE transaction, where we successfully helped institutionalize the company with some marquee shareholders, many of which are still partners to the company today. In September 2018, Laidlaw acted as Co-Manager in a follow-on offering for $72,187,5003 and again in April 2021 for $125,000.0004. Laidlaw’s Capital Markets team has stayed committed to continuing to working with the team at ALDX to make relevant introductions, build awareness in the name, and be a supportive long-term partner to the company.

MTEM is a clinical stage Biotechnology company focused on the discovery, development and commercialization of next generation immunotoxins called engineered toxin bodies (ETBs for the treatment of cancer. Backed by a very strong syndicate of investors, MTEM went public via Reverse Merger in August 2017. In June of 2018 we were introduced to MTEM by a board member of the company. This same board member appreciated the work we had done for a couple other companies where he is also a board member and thought we could be a value-add partner. At the time that we met in mid-2018, in our opinion, they were under followed and undervalued. We then consummated a robust 2-3-month Non-Deal roadshow and in September of 2018, MTEM raised ~$45,000,000 to strengthen what was already a strong balance sheet. This follow-on offering was led by Cowen and Company, Evercore and UBS and Laidlaw acted as Lead Manager. Many of the healthcare centric institutions that we introduced MTEM to participated in the financing in a meaningful way. The company continued to work with their financial sponsors, and also add of a couple strategic partnerships to their story throughout 2019 and In November of 2019, MTEM successfully Raised $50,000,000 lead by Cowen, Barclays and Stifel. Laidlaw acted as a Financial Advisor on the transaction. We continue to pound the table on the name and be a supportive partner to the company.

Go to MTEM.com

Athenex Inc (ATNX) is a Global Biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. They are working to bring innovative cancer treatments (Oral Taxil) to the market and improve health outcomes. Senior members of the Laidlaw Capital markets team have had a long standing relationship with ATNX for years but the team officially started working with ATNX in 2H2017. What we realized was that while ATNX had a robust pipeline, many supportive shareholders in Asia, a stellar CEO and an exciting story, they seemed to be under the radar and in our opinion under-valued. We initiated coverage in September of 2017 and quickly rolled our sleeves up and started making relevant introductions. Since 2H2017, the Laidlaw Capital Markets team, has hosted more than 50 Meetings and calls for the company. In the process of making these introductions, we were able to add over 10 new page 1 and page 2 shareholders to the company’s cap table with tier 1 marquee name Healthcare centric institutional investors, who collectively have invested over $250mm into the company. In 1Q2018, ATNX raised $75mm in a follow-on offering lead by RBC, DB and Needham. Laidlaw acted as a co-manager on the transaction. Then in mid-2018, after facilitating many meetings with an investor who continues to be a supportive page 1 holder, we were exclusive placement agent on a $100,000,000 Debt and equity Hybrid private placement for ATNX. This was the largest debt and equity Hybrid transaction the fund had done to date and a huge win for ATNX not just from a balance sheet perspective but for their brand as well. In addition to the follow-on offering and private placement, Laidlaw effected a multiple block trade.

Go to MTEM.com

In May of 2014 Aldeyra Therapeutics (ALDX), a late stage clinical development biotechnology company developing and commercializing next generation medicines for patients with immune mediated, ocular and systemic diseases completed a $12,000,000, retail centric IPO. Since then, the company has raised over $125,000,000. Following the company’s IPO, Laidlaw’s capital markets team was introduced to (ALDX) and consummated a robust healthcare centric institutional roadshow effort. After 50+ introductions to potential investors, in January 2015 Laidlaw was exclusive placement agent on their first financing since their IPO – a $8mm PIPE transaction, where we successfully helped institutionalize the company with some marquee shareholders, many that are still partners to the company today. Laidlaw Capital Markets team has stayed committed to continuing to working with the team at ALDX to make relevant introductions, build awareness in the name and be a supportive sponsor to the company. Please find a timeline of the relationship via the View Timeline button. Click on the Aldeyra logo to check out their site.